FDA 批准药物在实验室中通过干扰细胞回收机制杀死癌细胞
FDA-approved drug kills cancer cells in lab by disrupting cellular recycling
VCU Massey Comprehensive Cancer Center 研究人员发现,FDA 批准的 eliglustat 可以通过减少癌细胞中的 GCS 来诱导细胞死亡,而非通过积累 ceramide。进一步研究表明,抑制 GCS 可以导致癌细胞的溶酶体功能障碍,从而诱导癌细胞死亡。该发现可能对正在进行的 eliglustat 与免疫治疗联合的临床试验产生影响。
首次揭示 GCS 抑制剂通过干扰细胞回收机制诱导癌细胞死亡,可能为肿瘤治疗提供新策略。
Researchers from VCU Massey Comprehensive Cancer Center recently demonstrated that the inhibition of glucosylceramide synthase (GCS) can cause death in cancer cells that is independent of changes in pro-death ceramide levels. The findings, which were recently published in Cell Death Discovery, showed that using eliglustat, an FDA-approved drug, induced cell death in several cancer cell lines. Additionally, the findings demonstrated, for the first time, that GCS and its products had a pro-survival role in cancer cells.
"This is exciting, because it has clinical impact," said Alexandra Straus, Ph.D., a postdoctoral fellow in the VCU Department of Cellular, Molecular and Genetic Medicine, who is also a collaborator on the paper. "As scientists that are at the bench, it's important to think about how a clinical trial might be working, and these findings can help us identify potential biomarkers for understanding which patients might benefit most."
What are the main findings of this research?
Researchers in the lab of Can Senkal, Ph.D., interim director of the Lipidomics and Metabolomics Shared Resource and member of the Cancer Biology research program at Massey, treated cancer cell lines that represent primary focuses in Massey's catchment area—colon, ovarian and cervical cells—with eliglustat, a known inhibitor of GCS.
Eliglustat is typically used for the treatment of Gaucher disease type 1, a disease that occurs when a person has too little of the enzyme that breaks down glucosylceramide.
They found that eliglustat caused the cancer cells to die, not through ceramide accumulation as previously thought, but rather by decreasing glucosylceramide in the cells. Further study by the Massey team showed that cancer cells initially treated with eliglustat had lysosomes that appeared as enlarged vesicles because they could not degrade any cellular materials.
Because cancer cells rely on lysosomes to recycle cellular components, researchers showed that inhibiting GCS via eliglustat prevents lysosomes from functioning properly, thereby inducing cancer cell death.
"Healthy cells need to have proper lysosomal function," Senkal explained. "And cancer cells, since they grow so fast, they depend on this degradation process, so they need a healthy lysosome to keep up with their growth needs. And we think GCS or the complex glycosphingolipids have a role in maintaining the proper function of the lysosomes.
"And so, when the cancer cells do not have the GCS, they do not have the properly functioning lysosomes, and therefore, they die."
Potential impact
These findings could have clinical impact in several ongoing clinical trials that feature eliglustat in combination with immunotherapy. Additionally, this research could be used to develop biomarkers for patients and to determine cancer cell signatures in which these findings can best be applied.
What's next?
Researchers from Massey's Cancer Biology and Development Therapeutics research programs are working to identify opportunities to further this research, likely by collaborating with outside companies or partners for clinical-grade compounding before further study could offer opportunities for clinical trials.
Additionally, analysis of patient metabolites could provide a mechanism for developing biomarkers to determine which patients have the lipid profile that might benefit from eliglustat.
More information
Alexandra J. Straus et al., Targeting glucosylceramide generation induces cancer cell death through lysosomal dysfunction independent of ceramide accumulation, Cell Death Discovery (2026). DOI: 10.1038/s41420-026-03313-6
Key medical concepts
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: FDA-approved drug kills cancer cells in lab by disrupting cellular recycling (2026, November 9) retrieved 9 November 2026 from https://medicalxpress.com/news/2026-11-fda-drug-cancer-cells-lab.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com